Trial · NCT02164422

Does Guanfacine Attenuate Stress-Induced Drinking?

NCT02164422, Phase 2, Completed, Yale University; results first posted 2021-04-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Does Guanfacine Attenuate Stress-Induced Drinking? Trials, record NCT02164422. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02164422

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Does Guanfacine Attenuate Stress-Induced Drinking?
NCT number: NCT02164422
Status: Completed
Phases: Phase 2
Enrollment: 70 participants, actual
Lead sponsor: Yale University
Conditions: Alcohol Drinking
Interventions: Guanfacine 3mg/day, Guanfacine 1.5mg/day, Placebo
First posted: 2014-06-16
Last updated: 2021-07-08
Results first posted: 2021-04-21

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	mL Per 15 Minutes	2 hour self administration period during lab sessions held on days 22 and 25	mL per 15 minutes during 2-hour ad-lib drinking period

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	mL Per 15 Minutes	2 hour self administration period during lab sessions held on days 22 and 25		mls of alcohol consumed per 15 minutes	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
mL Per 15 Minutes	Guanfacine 3mg/Day	85.850	Standard Error 5.217	mls of alcohol consumed per 15 minutes
mL Per 15 Minutes	Guanfacine 1.5mg/Day	80.575	Standard Error 5.567	mls of alcohol consumed per 15 minutes
mL Per 15 Minutes	Placebo	114.104	Standard Error 5.268	mls of alcohol consumed per 15 minutes

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Guanfacine 3mg/Day	25
Overall Study	STARTED	Guanfacine 1.5mg/Day	22
Overall Study	STARTED	Placebo	23
Overall Study	COMPLETED	Guanfacine 3mg/Day	24
Overall Study	COMPLETED	Guanfacine 1.5mg/Day	20
Overall Study	COMPLETED	Placebo	23
Overall Study	NOT COMPLETED	Guanfacine 3mg/Day	1
Overall Study	NOT COMPLETED	Guanfacine 1.5mg/Day	2
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events15

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	somnolence	General disorders	Guanfacine 3mg/Day	0	25	0
other	somnolence	General disorders	Guanfacine 1.5mg/Day	0	22	0
other	somnolence	General disorders	Placebo	1	23	1
other	fatigue	General disorders	Guanfacine 3mg/Day	1	25	1
other	fatigue	General disorders	Guanfacine 1.5mg/Day	0	22	0
other	fatigue	General disorders	Placebo	2	23	2
other	dizziness	General disorders	Guanfacine 3mg/Day	1	25	1
other	dizziness	General disorders	Guanfacine 1.5mg/Day	0	22	0
other	dizziness	General disorders	Placebo	0	23	0
other	dry mouth	Gastrointestinal disorders	Guanfacine 3mg/Day	1	25	1

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Guanfacine 3mg/Day	0	25
Total, all-cause mortality	Guanfacine 1.5mg/Day	0	22
Total, all-cause mortality	Placebo	0	23
Total, other adverse events	Guanfacine 3mg/Day	3	25
Total, other adverse events	Guanfacine 1.5mg/Day	2	22
Total, other adverse events	Placebo	3	23
Total, serious adverse events	Guanfacine 3mg/Day	0	25
Total, serious adverse events	Guanfacine 1.5mg/Day	0	22
Total, serious adverse events	Placebo	0	23

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01AA022285	Does Guanfacine, an alpha2 adrenergic agonist, attenuate stress-induced drinking?	MCKEE, SHERRY ANN	YALE UNIVERSITY	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM	2014 to 2017

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02164422

GET https://conductscience.org/api/trials/v1/NCT02164422/registered

API reference For AI assistants